Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Pidilizumab (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 09 Apr 2015 Status changed from active, no longer recruiting to discontinued as per M.D. Anderson Cancer Center.
- 31 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 25 Mar 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History